Establishing Direct-to and from-Patient Clinical Trials (Part 2)

Update: 2024-02-21

Description

In Part 2, Mike Sweeney, QuickSTAT’s Global Head of Strategy for CGT and Direct to Patient products, offers specific supply chain design ideas and tactics to establish processes and overcome potential logistics roadblocks. He breaks down extraordinary case studies, and gives his views on what’s next – particularly around regulation.

Comments

In Channel

Powering the Future: Renewable Energy Supply Chain Logistics (Part 2)

2024-11-1924:24

Powering the Future: Renewable Energy Supply Chain Logistics (Part 1)

2024-10-2524:40

Driving Change: Adapting to the evolving automotive supply chain

2024-09-2616:23

Setting Up a Robust CGT Supply Chain (Part 2)

2024-08-2218:02

Setting Up a Robust CGT Supply Chain (Part 1)

2024-06-3018:18

The Logistics of Cell & Gene Therapy – From Benchmarking to Standardization (Part 2)

2024-05-3021:25

The Logistics of Cell & Gene Therapy – From Benchmarking to Standardization (Part 1)

2024-05-1324:53

Establishing Direct-to and from-Patient Clinical Trials (Part 2)

2024-02-2112:44

Establishing Direct-to and from-Patient Clinical Trials (Part 1)

2024-02-2125:59

00:00

Establishing Direct-to and from-Patient Clinical Trials (Part 2)

#box-pro-ellipsis-175986721412771{-webkit-line-clamp:2;}Establishing Direct-to and from-Patient Clinical Trials (Part 2)

Establishing Direct-to and from-Patient Clinical Trials (Part 2)

Quick Group of Companies

Establishing Direct-to and from-Patient Clinical Trials (Part 2)